The offering totals $45,000,000 before fees. The prospectus discloses a restatement of 2025 financial statements, a material weakness in internal control and going concern doubt.
Retension Pharmaceuticals, a Falls Church, Virginia developer of a hypertension drug, filed a Form S-1 on September 18, 2026. The preliminary prospectus leaves the share count and price blank, and its 2025 financial statements have been restated.
Questions about Retension Pharmaceuticals
Has Retension Pharmaceuticals issued a going-concern warning?
Our latest story on this, dated Oct 9, 2026: "Retension Pharmaceuticals prices IPO of 3,750,000 shares at $12.00". The story links the filing or release it is based on. Read the story.
When did Retension Pharmaceuticals go public?
Our latest story on this, dated Oct 9, 2026: "Retension Pharmaceuticals prices IPO of 3,750,000 shares at $12.00". The story links the filing or release it is based on. Read the story.
Has Retension Pharmaceuticals raised money recently?
Our latest story on this, dated Oct 9, 2026: "Retension Pharmaceuticals prices IPO of 3,750,000 shares at $12.00". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Retension Pharmaceuticals?
Retension Pharmaceuticals, Inc. trades under the ticker RTSN on NASDAQ.
Where is Retension Pharmaceuticals listed?
Retension Pharmaceuticals, Inc. is listed on NASDAQ.
What is the SEC CIK of Retension Pharmaceuticals?
The SEC Central Index Key (CIK) for Retension Pharmaceuticals, Inc. is 2002988. Its filings are on SEC EDGAR.
Which country or territory is Retension Pharmaceuticals listed under?
Our directory records Retension Pharmaceuticals, Inc. under United States.
What does Retension Pharmaceuticals do?
Our directory classifies Retension Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Retension Pharmaceuticals?
The ISIN recorded for Retension Pharmaceuticals, Inc. is US76135H1005.
Does aibio.space cover Retension Pharmaceuticals?
aibio.space lists Retension Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Retension Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest Retension Pharmaceuticals (RTSN) stock news?
Our latest story on Retension Pharmaceuticals, dated Oct 9, 2026: "Retension Pharmaceuticals prices IPO of 3,750,000 shares at $12.00". The offering totals $45,000,000 before fees. The prospectus discloses a restatement of 2025 financial statements, a material weakness in internal control and going concern doubt. Source.
How long will Retension Pharmaceuticals's cash last?
From our story of Oct 9, 2026: The prospectus discloses a restatement of 2025 financial statements, a material weakness in internal control and going concern doubt. Source.
How much cash does Retension Pharmaceuticals have?
From our story of Oct 9, 2026: That is a longer runway than the company gave in its earlier filing, where cash of $13.5 million at June 30, 2026, down from $18.9 million at December 31, 2025, was not expected to fund operations for at least twelve months. Source.
Is Retension Pharmaceuticals a smaller reporting company?
SEC records list Retension Pharmaceuticals, Inc.'s filer category as: <br>Emerging growth company.
Investor discussion: Retension Pharmaceuticals
Members talk about Retension Pharmaceuticals (RTSN). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Retension Pharmaceuticals, newest first. Each line links the filing it comes from.
Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:RTSN on TradingView.
SEC filings and registration
SEC name
Retension Pharmaceuticals, Inc.
CIK
2002988
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
RTSN (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
C/O REDUX THERAPEUTICS, LLC, MCLEAN, VA, 22101
Phone
(703) 624-2024
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Retension Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RTSN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio